cyclopentane has been researched along with Alzheimer Disease in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, S; Al-Harrasi, A; Ali, G; Khan, A; Ullah, R | 1 |
| Ann, J; Ha, HJ; Ha, JH; Hoang, VH; Jang, TH; Kim, H; Kim, YH; Lee, J; Ngo, VTH; Song, JY; Van Manh, N | 1 |
| Mo, Z; Quan, D; Shao, H; Sun, Y; Wang, J; Xu, K; Xu, L; Yu, J; Zhang, W; Zhuang, C | 1 |
| Chen, L; Cui, W; Fang, F; He, S; Huang, C; Liu, F; Naman, CB; Shentu, J; Sun, C; Wang, M; Wang, Q; Wang, Y; Xu, S; Yan, S; Zhao, J | 1 |
| Aderibigbe, AO; Adewole, FA; Ajayi, AM; Eduviere, AT; Umukoro, S | 1 |
| Cao, Z; Cui, C; Hou, Y; Klein, WL; Lacor, PN; Lao, L; Luo, Y; Tchantchou, F | 1 |
| Ahlemeyer, B; Krieglstein, J | 1 |
| Campbell, AM; Danysz, W; Diamond, DM; Park, CR; Schaefer, D; Zoladz, PR | 1 |
| Blackwell, TS; Brooks, JD; Brunoldi, E; Joo, M; McLaughlin, B; Milne, GL; Montine, TJ; Morrow, JD; Musiek, ES; Porta, A; Vidari, G; Zanoni, G | 1 |
| Caporaso, GL; De Camilli, P; Gandy, SE; Greengard, P; Matteoli, M; Mundigl, O; Takei, K | 1 |
| Beyreuther, K; Dyrks, E; Dyrks, T; Mönning, U; Turner, J; Urmoneit, B | 1 |
| Cook, DG; Doms, RW; Forman, MS; Iwatsubo, T; Kolson, DL; Lee, VM; Leight, S; Sung, JC | 1 |
| Beyreuther, K; Cappai, R; Culvenor, JG; Davis, JB; Evin, G; Karran, EH; Maher, F; Malchiodi-Albedi, F; Masters, CL; Roberts, GW; Underwood, JR | 1 |
| Kawamura, Y; Komano, H; Oyama, F; Saido, TC; Sakaki, Y; Sato, S; Sudoh, S; Wang, R; Yanagisawa, K | 1 |
1 review(s) available for cyclopentane and Alzheimer Disease
| Article | Year |
|---|---|
Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Apoptosis; Brain Ischemia; Cells, Cultured; Cyclopentanes; Diterpenes; Dose-Response Relationship, Drug; Drug Interactions; Flavones; Flavonoids; Furans; Ginkgo biloba; Ginkgolides; Glutamic Acid; Humans; Hypoxia; Lactones; Neurons; Neuroprotective Agents; Plant Extracts; Time Factors | 2003 |
13 other study(ies) available for cyclopentane and Alzheimer Disease
| Article | Year |
|---|---|
Cyclopentanone Derivative Attenuates Memory Impairment by Inhibiting Amyloid Plaques Formation in the 5xFAD Mice.
Topics: Alzheimer Disease; Animals; Cyclopentanes; Disease Models, Animal; Memory Disorders; Mice; Mice, Transgenic; Plaque, Amyloid | 2021 |
Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
Topics: Alzheimer Disease; Aminoacyltransferases; Amyloid beta-Peptides; Animals; Benzimidazoles; Cyclopentanes; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Humans; Male; Mice; Mice, Inbred ICR; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship | 2021 |
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Apoptosis; Benzothiazoles; Cyclopentanes; Humans; Mice; Necroptosis; Receptor-Interacting Protein Serine-Threonine Kinases | 2022 |
5-Hydroxycyclopenicillone Inhibits β-Amyloid Oligomerization and Produces Anti-β-Amyloid Neuroprotective Effects In Vitro.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cell Survival; Cyclopentanes; Fungi; Humans; Molecular Dynamics Simulation; Neurons; Neuroprotective Agents | 2017 |
Methyl jasmonate enhances memory performance through inhibition of oxidative stress and acetylcholinesterase activity in mice.
Topics: Acetates; Alzheimer Disease; Analysis of Variance; Animals; Biomarkers; Brain; Catalase; Cholinesterase Inhibitors; Cyclopentanes; Male; Malondialdehyde; Maze Learning; Memory; Mice; Oxidative Stress; Oxylipins; Recognition, Psychology; Scopolamine; Superoxide Dismutase | 2015 |
Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons.
Topics: Alzheimer Disease; Animals; Blotting, Western; Cyclic AMP Response Element-Binding Protein; Cyclopentanes; Dose-Response Relationship, Drug; Furans; Ginkgo biloba; Ginkgolides; Hippocampus; Mice; Neurogenesis; Phosphorylation; Plant Extracts; Quercetin; Rats; Rats, Sprague-Dawley; Synapses | 2009 |
Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane.
Topics: Alzheimer Disease; Animals; Brain-Derived Neurotrophic Factor; Cyclopentanes; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Long-Term Potentiation; Male; Maze Learning; Memantine; Memory; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2006 |
Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid.
Topics: Alzheimer Disease; Animals; Cell Line; Cyclooxygenase 2; Cyclopentanes; Docosahexaenoic Acids; Electrons; Humans; I-kappa B Kinase; Inflammation; Lipid Peroxidation; Lipopolysaccharides; Macrophages; Mice; Molecular Structure; NF-kappa B; Nitric Oxide Synthase Type II; Signal Transduction | 2008 |
Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor protein.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Axons; Brain; Brefeldin A; Cell Line; Cells, Cultured; Cyclopentanes; Dendrites; Golgi Apparatus; Intracellular Membranes; Neurons; Rats; Rats, Sprague-Dawley | 1994 |
Generation of beta A4 from the amyloid protein precursor and fragments thereof.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Brefeldin A; Culture Media, Conditioned; Cyclopentanes; Gene Expression; Humans; Kinetics; Methylamines; Monensin; Neuroblastoma; Peptide Fragments; Plasmids; Transfection; Tumor Cells, Cultured | 1993 |
Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Base Sequence; Brefeldin A; Cell Compartmentation; Cell Line; Cyclopentanes; DNA Primers; Endoplasmic Reticulum; Humans; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Neurons; Peptide Fragments; Protein Synthesis Inhibitors | 1997 |
Alzheimer's disease-associated presenilin 1 in neuronal cells: evidence for localization to the endoplasmic reticulum-Golgi intermediate compartment.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antibodies, Monoclonal; Antibody Specificity; Biological Transport; Biomarkers; Brefeldin A; Cell Compartmentation; Cerebellum; CHO Cells; Cricetinae; Cyclopentanes; Endoplasmic Reticulum; Fluorescent Antibody Technique; Golgi Apparatus; Hippocampus; Humans; Mannose-Binding Lectins; Membrane Proteins; Neuroblastoma; Neurons; Presenilin-1; Protein Synthesis Inhibitors; Rabbits; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured | 1997 |
Presenilin 1 mutations linked to familial Alzheimer's disease increase the intracellular levels of amyloid beta-protein 1-42 and its N-terminally truncated variant(s) which are generated at distinct sites.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Bacterial Agents; Brefeldin A; Cyclopentanes; Extracellular Space; Gene Expression Regulation; Genetic Linkage; Humans; Intracellular Fluid; Macrolides; Membrane Proteins; Mice; Monensin; Mutation; Peptide Fragments; Presenilin-1; Time Factors; Tumor Cells, Cultured | 1998 |